MedTrace Logo

Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT07244926 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-11-24

No results posted yet for this study

Summary

In this single-arm, phase II study, we aimed to evaluate the efficacy and safety of sac-TMT plus bevacizumab in patients with advanced non-squamous NSCLC who showed disease progression on or after first-line ICI plus platinum-based chemotherapy.

Conditions

Interventions

DRUG

Sacituzumab tirumotecan plus bevacizumab

The eligible patients will receive intravenous sac-TMT 4mg/kg every 2 weeks plus intravenous bevacizumab 10mg/kg every 2 weeks until disease progression, death, unacceptable toxicity, or another treatment discontinuation criterion is met.

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Principal Investigators

  • Xiubao Ren, MD. Ph.D · Tianjin Medical University Cancer Institute and Hospital

  • Liang Liu, MD. Ph.D · Tianjin Medical University Cancer Institute and Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2027-06-30
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07244926 on ClinicalTrials.gov